Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patient (18 years and older)~2. Knee arthroscopy not combined with open surgery.~3. Patients eligible for surgical treatment.~4. Patients are willing and able to continue study participation to ensure completion of all procedures and observations required by the study.~5. Written informed consent~Exclusion Criteria:~1. Diagnostic arthroscopy~2. Patients concomitantly treated systemically with strong concurrent CYP3A4 and P-gp-inhibitors, i.e. azole-antimycotics or HIV protease inhibitors.~3. Hypersensitivity to the active substance or to any of the excipients of study drug~4. Pregnant women or breast-feeding.~5. Hepatic disease associated with coagulopathy and clinically relevant bleeding risk~6. Known thrombophilia (hereditary or acquired)~7. Mandatory anticoagulation.~8. Known severe bleeding tendency~9. Clinically significant active bleeding.~10. Severe renal failure (GFR\<30mL/min/1.73m2)~11. Patients participating in another clinical trial.~12. Recent mayor surgery (6 to 12 weeks)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Oral Rivaroxaban 10 mg od for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): oral placebo od for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).